Market Place
Sourcing Support
Processa Doses First NGC-Cap Patient In Breast Cancer Trial
02 Oct 2024 //
GLOBENEWSWIRE
Akeso`s Cadonilimab Plus Chemotherapy for Gastric Cancer Presented at 2024 AACR
08 Apr 2024 //
PR NEWSWIRE
Processa Provides Interim Analysis from Ongoing Phase 1b Trial of Capecitabine
19 Dec 2023 //
GLOBENEWSWIRE
Akeso`s bispecific notches ph. 3 victory against gastric cancer
08 Nov 2023 //
FIERCE BIOTECH
Ongoing Results From a Dose Expansion Cohort of CYT-0851
12 Oct 2023 //
BUSINESSWIRE
Trifluridine/Tipiracil Plus Bevacizumab Provides Potential 1st-Line Alternative
30 Aug 2023 //
ONCLIVE
Adjuvant Ibandronate Plus Capecitabine Does Not Significantly Improve OS
07 Jul 2023 //
ONCLIVE
Intas Pharmaceuticals Limited on FDA Import Alert List
06 Jun 2023 //
FDA
Preliminary Result with CYT-0851 in Advanced Solid Tumors Show Clinical Activity
03 Jun 2023 //
BUSINESSWIRE
Fusion and Cyteir refocus pipelines; Nona collaborating with PharmaEssentia
12 May 2023 //
ENDPTS
CARsgen`s CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA
05 May 2023 //
PR NEWSWIRE
Astellas’ Stomach Cancer Drug Zolbetuximab Notches Second Phase 3 Win
17 Dec 2022 //
PRESS RELEASE
FDA updates older Genentech cancer drug label
15 Dec 2022 //
ENDPTS
US FDA grants IND clearance for Aston Sci.’s Phase II cancer vaccine trial
05 Sep 2022 //
CLINICALTRIALSARENA
Aston gets US FDA nod to begin PII trial of therapeutic cancer vaccine AST-301
04 Sep 2022 //
PHARMABIZ
CG doses first patient in Phase Ib/II pancreatic adenocarcinoma therapy trial
19 Aug 2022 //
CLINICALTRIALSARENA
Enhertu strikes again with a PhIII success in another breast cancer population
16 Aug 2022 //
ENDPTS
NICE draft guidance recommends tucatinib for advanced breast cancer
25 Feb 2022 //
PHARMAFILE
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA
08 Dec 2021 //
BUSINESSWIRE
Tempus Introduces Diagnostic Test to Its Growing Collection of Algorithms
26 Oct 2021 //
BIOSPACE
NICE does not recommend tucatinib in new draft guidance
26 Oct 2021 //
EUROPEANPHARMACEUTICALREVIEW
Zanidatamab PII Trial Shows Promising Data in First-Line HER2-Positive GEA
16 Sep 2021 //
BUSINESSWIRE
Dr Reddys`s Generic Capecitabine Receives Approval In US
09 Dec 2020 //
FDA
RFI Rates In TOSCA Study Were Poorer In Elderly Compared With Younger Patients
20 Sep 2020 //
ESMO
EMA recommendations on DPD testing prior to treatment with fluorouracil
01 May 2020 //
EMA
US FDA approves Puma`s SNDA for neratinib in combo with capecitabine
28 Feb 2020 //
PHARMABIZ
EMA Validates Seattle Genetics’ Mkt Authorization Application for Tucatinib
31 Jan 2020 //
BUSINESSWIRE
Seattle Genetics` breast cancer drug hits mark in pivotal trial
21 Oct 2019 //
FIERCE BIOTECH
Armas Expands Generic Portfolio with Launches of Capecitabine and Imatinib
08 Apr 2019 //
PR NEWSWIRE
Puma Biotech Announces Top Line Results of Phase III NALA Trial of Neratinib
18 Dec 2018 //
BUSINESSWIRE
Accord Healthcare`s Generic Capecitabine Receives Approval in Europe
31 Oct 2018 //
EMA
MSN Labs Pvt Ltd’s Generic Capecitabine Receives Approval In The US
05 Jul 2018 //
FDA
TRIGR Therapeutics & ABL Bio Collaboration on Therapeutic Abs
02 Jul 2018 //
BUSINESSWIRE
Enforcement Report - Week of May 16, 2018
16 May 2018 //
FDA
Eugia Pharma`s Generic Capecitabine Receives Approval In US
19 Apr 2018 //
FDA
Seattle Genetics to Acquire Cascadian Therapeutics
01 Feb 2018 //
ENDPTS
Par Pharm’s Generic Capecitabine Receives Approval In US
01 Dec 2017 //
FDA
Alkem Lab’s Generic Capecitabine Receives Approval In US
29 Nov 2017 //
FDA
Amneal Pharms Generic Capecitabine Receives Approval In US
28 Feb 2017 //
FDA
AstraZeneca Phase III breast cancer trial met primary endpoint
23 Feb 2017 //
EUROPEAN PHARMACEUTICAL
ASLAN posts positive top-line varlitinib phase 2 data in breast cancer
16 Feb 2017 //
FIERCE PHARMA
Shilpa`s Generic Capecitabine Receives Approval In US
12 Dec 2016 //
FDA
Pfizer’s First-in-class Breast Cancer Therapy Wins EU Licensing
11 Nov 2016 //
PMLIVE
Life-extending breast cancer drug approved by NICE
03 Nov 2016 //
EU PHARMACEUTICAL REVIEW
List Of Drugs Approved By Anvisa
03 Oct 2016 //
ANVISA
Zhejiang Hisun Pharmaceutical, Co., Ltd. (Yantou Campus) Fails EDQM Inspection
19 Sep 2016 //
EDQM
Formulation & Development of Colon Specific Multiparticulate Sys of Capecitabine
19 Sep 2016 //
PHARMA-EXCIPIENTS
Welsh gov overrules NICE rejection of Celgene`s pancreatic cancer drug
18 Mar 2016 //
PHARMATIMES
Dr Reddy`s plans to pursue inorganic opportunities
17 Feb 2016 //
BUSINESS STANDARD
Incyte decides to discontinue JANUS studies of ruxolitinib plus capecitabine
15 Feb 2016 //
CPHI ONLINE
12 cancer drugs may come under price control
05 May 2015 //
THE INDIAN EXPRESS
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
02 May 2015 //
FIERCE PHARMA MFG
Accord`s Generic Capecitabine (150 Mg, 500 Mg) Approved in USA For Cancer
30 Apr 2015 //
FDA
Colorectal Cancer: What You Should Know
21 Apr 2015 //
FDA
BUZZ-India`s Dr.Reddy`s up on hopes of US FDA resolution of Srikakulam plant
30 Mar 2015 //
REUTERS
FDA Grants Breakthrough Therapy Designation for Roche’s Investigational Cancer Immunotherapy MPDL3280A
04 Feb 2015 //
EUROPEAN PHARMACEUTICAL REVIEW
Roche Says Swiss Franc`s Surge May Erode Profit Growth This Year
29 Jan 2015 //
BLOOMBERG
